Mutation of p53 Acetylation Protects Against Angiotensin-II-Induced Cardiac Dysfunction and Fibrosis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199668 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Aubrey C Cantrell und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA. Hauptthemen laut MEDLINE: Angiotensin II, Tumor Suppressor Protein p53, Mutation. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Heart Lung and Blood Institute, National Institute of General Medical Sciences and National Heart, Lung, and Blood Institute, University of Mississippi Medical Center Intramural Research Support Program.
Abstract (Originalsprache)
Hypertension is a major risk factor for heart failure. Acetylation of p53 is known to regulate its activities. We have previously identified that p53 acetylation is required for cardiac remodeling in a mouse model of pressure overload-induced heart failure. Acetylation mutant p53 (p53aceKO) mice have been shown to have the ability to regulate SIRT3 KO-induced cardiac fibrosis. In the present study, we hypothesized that p53aceKO mice would exhibit cardiac protection and blunt cardiac fibrosis when subjected to Ang-II-induced hypertension. Control and p53aceKO mice received either a micro-osmotic pump implant administering Ang-II for 28 days or a sham procedure. Blood pressure was measured weekly, and echocardiography was performed every two weeks. Mice were euthanized and hearts were processed for histological analysis. While both control and p53aceKO mice receiving Ang-II exhibit increased systolic and diastolic blood pressures, control mice also demonstrate increases in ejection fraction and fractional shortening compared to the sham, while p53aceKO mice do not. Furthermore, control mice receiving Ang-II exhibit decreased left ventricular diameter and volume at end-systole and end-diastole, as well as thickening of both the anterior and posterior walls, while p53aceKO mice exhibit no significant changes in any of these parameters. Additionally, p53aceKO mice do not exhibit the Ang-II infusion-induced cardiac fibrosis seen in control mice treated with Ang-II. Mutation of p53 acetylation is protective against Ang-II infusion-induced cardiac fibrosis and dysfunction in mice. Acetylated p53 may, therefore, be a novel therapeutic target to address complications in the heart associated with hypertension.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Mississippi Medical Center, 2500 North State Street, Jackson, MS 39216, USA.
ORCID-Profile: Quinesha A Williams, Jian-Xiong Chen, Heng Zeng
Förderung
- National Heart Lung and Blood Institute
- National Institute of General Medical Sciences and National Heart, Lung, and Blood Institute
- University of Mississippi Medical Center Intramural Research Support Program
Zitieren
APA
Cantrell, A. C., Williams, Q. A., Chen, J. X., & Zeng, H. (2025). Mutation of p53 Acetylation Protects Against Angiotensin-II-Induced Cardiac Dysfunction and Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199668
Vancouver
Cantrell AC, Williams QA, Chen JX, Zeng H. Mutation of p53 Acetylation Protects Against Angiotensin-II-Induced Cardiac Dysfunction and Fibrosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199668
BibTeX
@article{Cantrell2025,
author = {Cantrell, Aubrey C and Williams, Quinesha A and Chen, Jian-Xiong and Zeng, Heng},
title = {Mutation of p53 Acetylation Protects Against Angiotensin-II-Induced Cardiac Dysfunction and Fibrosis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199668}
}
EUVIMED